Off-the-shelf multi-virus specific T cells following haematopoietic stem cell tr...
Dr Bilal Omer - Baylor College of Medicine, Houston, USA
8 Dec 2020
Blinatumomab and oral TKIs for the treatment of Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
8 Dec 2020
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
8 Dec 2020
Real world management of multiple myeloma patients
Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
8 Dec 2020
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-ye...
Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
7 Dec 2020
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patien...
Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
7 Dec 2020
FORTE trial: Impact of minimal residual disease on multiple myeloma patients
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
7 Dec 2020
Evaluation of MRD negativity in patients with relapsed or refractory multiple my...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
7 Dec 2020
ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma
Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma
Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA
7 Dec 2020
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in ne...
Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
7 Dec 2020
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelph...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
7 Dec 2020
